India’s Dr Reddy’s beats Q4 profit view; names new CFO
The company’s U.S. sales have been boosted by persistently strong demand for Lenalidomide, a generic version of Bristol-Myers Squibb’s (BMY.N) blockbuster cancer drug Revlimid, which was launched in 2022.